Research chemicalResearch chemicalDissociative

DMXE (Deoxymethoxetamine)

Also known as Deoxymethoxetamine · 3-Me-2'-Oxo-PCE analogue

Written by enwyReviewed 4 Aug 20261 sources0 comments

DMXE (deoxymethoxetamine, a 3-methoxy analogue in the MXE/PCE family) is a dissociative research chemical closely related to methoxetamine. Like other arylcyclohexylamines it acts as an NMDA receptor antagonist, producing dissociation, analgesia and, at higher doses, immersive dissociative states. Human safety data are minimal.

01 Overview

DMXE appeared on the research-chemical market as a successor to methoxetamine-type dissociatives after tighter controls on earlier analogues. It is reported to have a longer duration than ketamine and to produce strong dissociative effects.

Formal pharmacological and toxicological data are essentially absent, so potency, metabolism and long-term risks are unknown. Concerns common to the MXE family include cardiovascular stimulation, dissociative 'holes' at high doses, and possible urinary or cognitive effects with heavy repeated use.

02 Mechanism

Arylcyclohexylamine NMDA receptor antagonist reducing glutamatergic excitatory transmission, producing dissociation and anaesthesia.

03 Dosing

Tier	Dose	Route	Notes
Light	10–25 mg	Insufflated	Anecdotal.
Common	20–50 mg	Oral	Anecdotal only; long duration and delayed onset reported.

04 Effects

Effect	Magnitude	Evidence
DissociationDetachment from body and surroundings.		Anecdotal
EuphoriaMood elevation reported at moderate doses.		Anecdotal
AnalgesiaReduced pain perception.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Psychological dependence and compulsive redosingCraving and repeated dosing sprees reported across the MXE family.	Moderate	Common with heavy use	Anecdotal
Dissociative anaesthesia and injury riskHeavy dissociation, ataxia and confusion at high doses raise injury and aspiration risk.	Severe	Uncommon, dose-dependent	Anecdotal
Tachycardia and hypertensionRaised heart rate and blood pressure typical of dissociatives.	Moderate	Common	Anecdotal

06 Legal status

United States

Not scheduled by name

Possible analogue treatment under federal law. · as of Jan 2026

United Kingdom

Psychoactive Substances Act

Covered by blanket psychoactive substances legislation. · as of Jan 2026

07 References

Methoxetamine and analogues: dissociative NPS reviewHuman Psychopharmacology / review literature

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.